Noida Chronicle

Fabry Disease Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics

 Breaking News
  • No posts were found

Fabry Disease Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics

January 16
19:57 2023
Fabry Disease Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics
The Fabry Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fabry Disease pipeline products will significantly revolutionize the Fabry Disease market dynamics.

DelveInsight’s “Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Fabry Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Fabry Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fabry Disease Market Insights

 

Fabry Disease Overview

Fabry disease is an inherited lysosomal storage disease caused by a nonfunctional or partially functional enzyme, alpha-galactosidase A (α-Gal A). Decreased activity of α-Gal A in lysosomes results in the accumulation of enzyme substrates (Gb3 and lyso-Gb3) which cause cellular damage in tissues throughout the body.

 

Some of the key facts of the Fabry Disease Market Report: 

  • The Fabry Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to DelveInsight’s analysis showed that in Japan, the highest cases of Fabry Disease were found in 10-19 age group in 2021, followed by
  • There were ~450 prevalent cases of Fabry Disease in Japan in 2021
  • Key Fabry Disease Companies: Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, and others
  • Key Fabry Disease Therapies: PRX-102, AVR-RD-01, Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, and others
  • The Fabry Disease epidemiology based on gender analyzed that Fabry Disease is more prevalent in males than females

 

Get a Free sample for the Fabry Disease Market Report – 

https://www.delveinsight.com/sample-request/fabry-disease-market

 

Key benefits of the Fabry Disease Market report:

  1. Fabry Disease market report covers a descriptive overview and comprehensive insight of the Fabry Disease Epidemiology and Fabry Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Fabry Disease market report provides insights on the current and emerging therapies.
  3. Fabry Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Fabry Disease market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Fabry Disease market.

 

Download the report to understand which factors are driving Fabry Disease epidemiology trends @ Fabry Disease Epidemiological Insights 

 

Fabry Disease Market  

The dynamics of the Fabry Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

Agalsidase Beta BS-IV Infusion (JCR Pharmaceuticals/GlaxoSmithKline), developed as a biosimilar of Fabrazyme biosimilar, has been available in Japan since 2018, decreasing the burden on the patients with improved access.”

 

Fabry Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Fabry Disease Epidemiology Segmentation:

The Fabry Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Fabry Disease
  • Prevalent Cases of Fabry Disease by severity
  • Gender-specific Prevalence of Fabry Disease
  • Diagnosed Cases of Episodic and Chronic Fabry Disease

 

Fabry Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fabry Disease market or expected to get launched during the study period. The analysis covers Fabry Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fabry Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Fabry Disease market share @ Fabry Disease market forecast

 

Fabry Disease Therapies and Key Companies

  • PRX-102: Protalix Biotherapeutics
  • AVR-RD-01: AVROBIO
  • Venglustat: Sanofi Genzyme
  • ST-920: Sangamo Therapeutics
  • FLT190: Freeline Therapeutics
  • 4D-310: 4D Molecular Therapeutics
  • Lucerastat: Idorsia Pharmaceuticals
  • Moss-aGal: Greenovation Biotech GMBH

 

Fabry Disease Market Strengths

  • Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Fabry disease
  • Newborn screening for Fabry disease has been implemented in several countries, enabling the early detection of individuals with Fabry mutations
  • Many therapies are under investigation in various phases of clinical trials. These include pegylated forms of α-GAL, gene therapy, and substrate reduction therapy

 

Scope of the Fabry Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Fabry Disease Companies: Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, and others
  • Key Fabry Disease Therapies: PRX-102, AVR-RD-01, Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, and others
  • Fabry Disease Therapeutic Assessment: Fabry Disease current marketed and Fabry Disease emerging therapies
  • Fabry Disease Market Dynamics: Fabry Disease market drivers and Fabry Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Fabry Disease Unmet Needs, KOL’s views, Analyst’s views, Fabry Disease Market Access and Reimbursement 

 

Fabry Disease Market Unmet Needs

  • Challenges in diagnosis
  • Development of novel therapies
  • Limitations in gene therapy
  • Poor disease understanding
  • Clinical biomarkers 

 

Table of Contents 

1. Fabry Disease Market Report Introduction

2. Executive Summary for Fabry Disease

3. SWOT analysis of Fabry Disease

4. Fabry Disease Patient Share (%) Overview at a Glance

5. Fabry Disease Market Overview at a Glance

6. Fabry Disease Disease Background and Overview

7. Fabry Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Fabry Disease 

9. Fabry Disease Current Treatment and Medical Practices

10. Fabry Disease Unmet Needs

11. Fabry Disease Emerging Therapies

12. Fabry Disease Market Outlook

13. Country-Wise Fabry Disease Market Analysis (2019–2032)

14. Fabry Disease Market Access and Reimbursement of Therapies

15. Fabry Disease Market Drivers

16. Fabry Disease Market Barriers

17.  Fabry Disease Appendix

18. Fabry Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Fabry Disease treatment, visit @ Fabry Disease Medications 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles